However, most patients with EGFR mutations develop resistance to first-generation TKIs (erlotinib, gefitinib) or second-generation TKI (afatinib) with the emergence of resistance mutations in EGFR (i.e., p.T790M) in approximately 60% of the patients [38], cMET alterations [39], or transformation to small-cell lung cancer (SCLC) [40]. Here, EGFR is linked to small cell lung carcinoma.